← CytomX Therapeutics, Inc. (CTMX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CytomX Therapeutics, Inc. (CTMX)
Pharmaceutical Preparations · market cap $610M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
CytomX Therapeutics (CTMX) is a clinical-stage biotech developing Probody therapeutics — masked antibody-drug conjugates and immuno-oncology agents designed to activate preferentially in the tumor microenvironment. Its two lead assets, CX-2009 and CX-2029, are both in Phase 2 for solid tumor indications. With only $28.8M in cash and a stated runway of approximately 3.4 months, the company faces acute near-term financing pressure at a $745M market cap.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CX-2009 | Phase 2 | Neoplasms |
| CX-2029 | Phase 2 | Solid Tumor, Adult |
Price & technical context
3-month
-31.8%
6-month
-43.0%
12-month
-22.4%
52-wk range
$2.60–$6.75
vs 50-day MA
-18.8%
vs 200-day MA
-35.9%
Realized vol
84.0%
Max drawdown
-67.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CTMX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.